These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15679172)

  • 1. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?
    Hutzler M; Messing DM; Wienkers LC
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):51-8. PubMed ID: 15679172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    Grime KH; Bird J; Ferguson D; Riley RJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances.
    Obach RS
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):81-9. PubMed ID: 19152216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
    Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
    J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular models for ADMET predictions and evaluation of drug-drug interactions.
    Riley RJ; Kenna JG
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):86-99. PubMed ID: 14982152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting in vivo drug interactions from in vitro drug discovery data.
    Wienkers LC; Heath TG
    Nat Rev Drug Discov; 2005 Oct; 4(10):825-33. PubMed ID: 16224454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pivotal role of hepatocytes in drug discovery.
    Soars MG; McGinnity DF; Grime K; Riley RJ
    Chem Biol Interact; 2007 May; 168(1):2-15. PubMed ID: 17208208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
    Dambach DM; Andrews BA; Moulin F
    Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions.
    Jalaie M; Arimoto R; Gifford E; Schefzick S; Waller CL
    Methods Mol Biol; 2004; 275():449-520. PubMed ID: 15141126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.
    Emoto C; Murase S; Iwasaki K
    Xenobiotica; 2006 Aug; 36(8):671-83. PubMed ID: 16891248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.